An Immunotherapy Side Effect That Won't Reverse, in a Drug She Needs to Keep Taking
A single patient, three months into combination checkpoint-inhibitor therapy for melanoma, now hypophysitis-confirmed with new adrenal and thyroid axis failure. The disagreement is how to sequence replacement and whether her cancer treatment needs to pause for any of it.
A.T., a 61-year-old woman, retired from three decades as a labor-and-delivery nurse, and says flatly that the fatigue she's had for the past two weeks feels different from the ordinary tiredness she associates with chemotherapy — "a wrongness," is the phrase she uses, not a word she says lightly given how many exhausted patients she's cared for herself. She is three months into combination nivolumab and ipilimumab for stage IV melanoma, a regimen chosen specifically for its stronger response rates despite a known higher rate of immune-related adverse events than either drug alone. Labs drawn for her fatigue found a morning cortisol of 1.8 mcg/dL, undetectable ACTH, and a free T4 of 0.7 ng/dL with an inappropriately low-normal TSH — a pattern of combined central adrenal insufficiency and central hypothyroidism, not primary gland failure, and pituitary MRI showed mild diffuse gland enlargement consistent with hypophysitis, the recognized immune-related toxicity of checkpoint blockade rather than a coincidental new pituitary disease.
The two hormone axes she's lost carry genuinely different prognoses, a distinction worth being precise about rather than treating her hypophysitis as one uniform problem. In the specific pattern seen with combination ipilimumab-based therapy, ACTH deficiency is the axis most consistently reported as permanent — corticotroph destruction that does not reliably reverse even once the acute inflammatory phase settles, meaning her hydrocortisone replacement should be planned as lifelong from the outset, not tapered on a trial basis later. Central hypothyroidism and hypogonadism, by contrast, recover in a meaningful share of patients over the following months as the acute hypophysitis resolves, which argues against assuming her thyroid axis needs the same permanent framing applied to her cortisol deficiency. Both findings occurred without any MRI evidence of mass effect severe enough to threaten her vision, and high-dose glucocorticoid therapy for the hypophysitis itself — as opposed to physiologic replacement for the resulting deficiencies — has not been shown to improve pituitary function recovery and carries its own real risk of blunting her ongoing cancer immunotherapy's effect.
Replacing what's gone, without assuming all of it is gone for good
Start physiologic hydrocortisone replacement now, and plan for it as lifelong from day one rather than a taper trial. Her presentation — combination ICI therapy, undetectable ACTH, low cortisol — matches the pattern most consistently reported as permanent corticotroph loss; this isn't the axis I'd hedge on.
I'd hold off on committing levothyroxine to the same permanent framing — central hypothyroidism after checkpoint-inhibitor hypophysitis recovers in a real share of patients over the following months, so I'd replace it now for symptom relief but revisit whether she still needs it once the acute inflammation has had time to settle.
I'd add one thing to how this gets framed for her directly: this doesn't need to interrupt her immunotherapy. There's a real and understandable instinct to pause a drug that just caused a new problem, but hormone replacement corrects the deficiency the hypophysitis produced without addressing whatever underlying autoimmune process caused it — and unlike some other severe immune-related toxicities, isolated hypophysitis with adequate hormone replacement doesn't typically require holding checkpoint therapy, especially with a partial response already on the board.
The one thing I would push back on is reaching for high-dose glucocorticoids beyond physiologic replacement to try to treat the hypophysitis itself, the way you might for a more aggressive immune-related toxicity elsewhere.
Agreed, and I wasn't proposing that — physiologic replacement only, not a treatment-dose steroid course. High-dose glucocorticoids haven't been shown to improve pituitary function recovery in this specific toxicity the way they can for other immune-related adverse events, and using them anyway would risk blunting the antitumor response you're both counting on, for no proven pituitary benefit in return.
Agreed: physiologic hydrocortisone replacement planned as lifelong, given her presentation's match to the permanent-ACTH-deficiency pattern; levothyroxine started now with an explicit 6-month reassessment given central hypothyroidism's real recovery potential in this setting. Immunotherapy continues without interruption, and high-dose glucocorticoid treatment of the hypophysitis itself is explicitly not pursued.
Both physicians agreed fully on the plan; the oncologist's contribution was ensuring the framing given to A.T. herself doesn't leave her believing her cancer treatment is now in jeopardy because of a manageable hormone deficiency.